Redefining fatty liver disease: an international patient perspective

Shiha, Gamal; Korenjak, Marko; Eskridge, Wayne; Casanovas, Teresa; Vélez‐Möller, Patricia; Högström, Sari; Richardson, Ben; Munoz, Christopher; Sigurðardóttir, Sólveig; Coulibaly, A Q; Milan, Miskovikj; Bautista, Fabiana; Leung, Nancy; Mooney, Vicki; Obekpa, Solomon; Bech, Eva; Polavarapu, Naveen; Hamed, Abd Elkhalek; Radiani, Temur; Purwanto, Edhie; Bright, Bisi; Ali, Mohammad; Dovia, Cecil Kwaku; McColaugh, Lone; Koulla, Yiannoula; Dufour, Jean‐François; Soliman, Reham; Eslam, Mohammed

doi:10.1016/s2468-1253(20)30294-6

Cited by 142 publications

(115 citation statements)

References 55 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Overall, this proposal has been accepted many experts in the field and endorsed by the Asian Pacific Association for the Study of the Liver (APASL) 26‐33 . In addition, key patient organisations supported this change, as the new term is devoid of stigmatisation, confusion and trivialisation 34 . The new definition allows consideration of the possibility of coexistence other chronic liver diseases and recognises the heterogeneity of the disease.…”

Section: Brings Evidence To the Mafld‐nafld Debatementioning

confidence: 97%

The NAFLD‐MAFLD debate: Eminence vs evidence

Fouad

Elwakil

Elsahhar³

et al. 2020

Liver International

View full text Add to dashboard Cite

Debates are inevitable in science and could be a powerful tool for addressing controversial topics as it promotes critical thinking and inspires individuals to consider alternate viewpoints. However, debates can help only to identify the issues that need to be clarified to address this question, but it can never help resolve the controversy itself. In the era of evidence‐based medicine, the need for an evidence‐based debate is mandatory. Polarising opinions and major debate have recently arisen in hepatology on the nomenclature and diagnostic criteria for fatty liver disease associated with metabolic dysfunction (non alcoholic fatty liver disease [NAFLD]‐metabolic (dysfunction) associated fatty liver disease [MAFLD] debate). The aim of this viewpoint is to suggest a way to settle the debate through evidence. Descriptive review using PubMed to identify literature on the evidence and eminence‐based medicine and studies comparing MAFLD and NAFLD criteria. The emerging studies comparing the performance of diagnostic criteria of NAFLD and MAFLD represent the dawn of a new era for reframing the ongoing debate by acquisition of the mandatory evidence that will both resolve the debate and lead to novel avenues of research. In conclusion, the time has come to hold debate and focus on gathering and building the evidence to settle it. It does not matter who wins the debate and once there is robust evidence, we should all follow it wherever it leads.

show abstract

Section: Brings Evidence To the Mafld‐nafld Debatementioning

confidence: 97%

The NAFLD‐MAFLD debate: Eminence vs evidence

Fouad

Elwakil

Elsahhar³

et al. 2020

Liver International

View full text Add to dashboard Cite

show abstract

“…The recent landmark articles by Eslam et al 1,2 have attracted substantial attention from various stakeholders. [3][4][5][6][7][8][9] although concerns have been raised that such a change may lead to confusion, particularly among non-hepatologists. 10 To better assess physician awareness, perception of disease severity, patterns of practice for the diagnosis and management of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and to determine the impact of the proposed change in nomenclature, we undertook a national faceto-face survey from November 20, 2020 to December 20, 2020.…”

Section: To the Editormentioning

confidence: 99%

Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists

Fouad

Gomaa

Semida

et al. 2021

Journal of Hepatology

View full text Add to dashboard Cite

“…The global prevalence of T2DM is 8.8%, which translates into approximately 422 million afflicted people worldwide; the USA alone has a T2DM prevalence of 25% among its seniors and an alarming amount of obesity, with 604 million adults and 108 million children being obese. 1 Metabolic-associated fatty liver disease (MAFLD) affects 25% of the global population, [2][3][4][5][6][7][8][9] representing the principal cause of chronic liver disease. [10][11][12] This phenomenon can be associated with the modern lifestyle across industrialized countries that favors a sedentary life and high-calorie diets, thus promoting obesity and other chronic comorbidities.…”

Section: Introductionmentioning

confidence: 99%

Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases

Hernández-Ceballos¹,

Córdova-Gallardo²,

Méndez-Sánchez³

2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

The gut microbiome plays a key role in the health-disease balance in the human body. Although its composition is unique for each person and tends to remain stable throughout lifetime, it has been shown that certain bacterial patterns may be determining factors in the onset of certain chronic metabolic diseases, such as type 2 diabetes mellitus (T2DM), obesity, metabolic-associated fatty liver disease (MAFLD), and metabolic syndrome. The gut-liver axis embodies the close relationship between the gut and the liver; disturbance of the normal gut microbiota, also known as dysbiosis, may lead to a cascade of mechanisms that modify the epithelial properties and facilitate bacterial translocation. Regulation of gut microbiota is fundamental to maintaining gut integrity, as well as the bile acids composition. In the present review, we summarize the current knowledge regarding the microbiota, bile acids composition and their association with MAFLD, obesity, T2DM and metabolic syndrome.

show abstract

Redefining fatty liver disease: an international patient perspective

Cited by 142 publications

References 55 publications

The NAFLD‐MAFLD debate: Eminence vs evidence

The NAFLD‐MAFLD debate: Eminence vs evidence

Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists

Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases

Contact Info

Product

Resources

About